
    
      This is an open-label, phase II study to determine the toxicity and antitumor activity of
      ABI-007 100 mg/m2 administered weekly for 3 weeks followed by a rest week (4-week cycle) as
      first line therapy to patients with metastatic breast cancer in the following 2 cohorts:
      Patients who have received a taxane as part of their adjuvant therapy, and patients who did
      not receive a taxane as part of their adjuvant therapy. Patients will be assessed for
      antitumor response every 8 weeks.

      The last subject received study treatment 11DEC2012. The study was terminated on 31 May 2013
      via a notification letter to all investigators on 14 May 2013.
    
  